CI

At a glance

ClinicalIndex Comparison Record
Phase 1Unknown· 148 target
Drug / intervention
QLS1103drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05884801
NCT05884801Phase 1Unknown
CompareCT.gov

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of QLS1103 in Subjects With Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.·interventional·Posted Jun 1, 2023·Updated Aug 1, 2023

In Brief

A Phase 1 clinical trial evaluating QLS1103 for Advanced Solid Tumor. Targeting 148 participants across 1 site.

Detailed Summary

This study is a phase I, dose escalation and dose expansion study of QLS1103, to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QLS1103 in subjects with advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--

Timeline

Phase 1UnknownOverdue
202420252026
First PostedJun 1, 2023
Enrollment StartJun 30, 2023
Primary CompletionJan 30, 2025
Study CompletionJul 30, 2025
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 3.1 years ago

Interventions

QLS1103drug

Oral dose